Provided are a method which enables more accurate quantification of lipoprotein cholesterol in a test sample, and a quantification reagent and a quantification kit used for this method. The present invention provides a quantification method for lipoprotein cholesterol in a test sample containing a lipoprotein optionally using a quantification reagent, the method including adding a phospholipid to the test sample or the quantification reagent. The present invention also provides a quantification reagent for cholesterol in a lipoprotein used in the method of the present invention, the quantification reagent containing a phospholipid. The present invention also provides a quantification kit for lipoprotein cholesterol used in the method of the present invention, the quantification kit containing a phospholipid.

The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

Disclosed is a phosphatidic acid visualizing sensor configured to detect phosphatidic acid produced in a cell with high accuracy. The phosphatidic acid sensor an N-terminal region of -synuclein. Furthermore, the phosphatidic acid sensor includes a peptide having any one of following amino acid sequences (1) to (3): (1) an amino acid sequence of SEQ ID No. 2; (2) an amino acid sequence having 90% or more homology to the amino acid sequence of SEQ ID No. 2; and (3) an amino acid sequence in which 6 or less amino acids are deleted, substituted, and/or added to the amino acid sequence of SEQ ID No. 2.

The present invention provides a method for monitoring esophageal adenocarcinoma (EAC) disease progression in a subject, the method comprising: obtaining a biological sample from the subject; measuring with a quantitative analytical method at least one metabolite; determining a metabolomic biosignature of EAC disease progression based on a comparison of quantitative data for the at least one metabolite to corresponding data obtained for at least one reference sample; and identifying active EAC disease progression in the subject if the quantity of the at least one metabolite in the sample from the subject is greater than that found in the at least one reference sample.

The present invention relates to methods for diagnosing Respiratory Distress Syndrome of newborn.

A method of spectrometric analysis comprises obtaining one or more sample spectra for an aerosol, smoke or vapour sample. The one or more sample spectra are subjected to pre-processing and then multivariate and/or library based analysis so as to classify the aerosol, smoke or vapour sample. The results of the analysis are used for various surgical or non-surgical applications.

The present invention relates to new biomarkers for assessing ovarian cancer being more sensitive, particularly at early stage of disease. Moreover, the present invention relates to a method for assessing ovarian cancer from a patient to be examined, and to a kit for carrying out the method.

A system and method for using new biomarkers to assess individual diseases, including, but not limited to, a patient's prognosis before and/or after being diagnosed with the disease. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and/or treat various diseases, including, but not limited to, COVID-19.

The invention provides a lipid bilayer mimicking the lipid composition of the placenta. The lipid composition provides an in vitro placenta model using the lipid composition of the placental cell membrane.

A method of diagnosing cancer based on lipidomic analysis of a body fluid taken from the body of a patient is disclosed. The method includes the steps of spiking of the sample with a set of internal standards having at least one internal standard for each lipid class present in the sample, subsequently processing the sample by liquid-liquid lipidomic extraction or by solid phase lipidomic extraction, measurement of the processed sample by a mass spectrometry method, determining concentrations for at least 51, more preferably for all lipids present at a level above detection threshold of the mass spectrometry method, statistical evaluation of the determined concentrations of the lipids, the statistical evaluation determining the level of probability of the patient suffering from cancer, or optionally from a specific type of cancer.